Evidence map›Paper›PMID 39202011›Full record

ArticleJournal of personalized medicine2024

Detection and Characterization of Extracellular Vesicles in Sputum Samples of COPD Patients.

Ourania S Kotsiou, Katerina Katsanaki, Aikaterini Tsiggene, Sophia Papathanasiou, Erasmia Rouka, Dionysios Antonopoulos, Irene Gerogianni, Nikolaos A A Balatsos, Konstantinos I Gourgoulianis, Irene Tsilioni

Abstract read
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ourania S KotsiouLaboratory of Human Pathophysiology, Faculty of Nursing, University of Thessaly, 415 00 Larissa, Greece.ORCID 0000-0001-5219-6971
Katerina KatsanakiDepartment of Biochemistry, University of Thessaly, 415 00 Larissa, Greece.
Aikaterini TsiggeneDepartment of Biochemistry, University of Thessaly, 415 00 Larissa, Greece.
Sophia PapathanasiouDepartment of Respiratory Medicine, University of Thessaly, 415 00 Larissa, Greece.ORCID 0009-0005-3595-3738
Erasmia RoukaFaculty of Nursing, University of Thessaly, 415 00 Larissa, Greece.ORCID 0000-0003-2885-4510
Dionysios AntonopoulosDepartment of Biochemistry, University of Thessaly, 415 00 Larissa, Greece.
Irene GerogianniDepartment of Respiratory Medicine, University of Thessaly, 415 00 Larissa, Greece.
Nikolaos A A BalatsosDepartment of Biochemistry, University of Thessaly, 415 00 Larissa, Greece.ORCID 0000-0002-1146-1174
Konstantinos I GourgoulianisDepartment of Respiratory Medicine, University of Thessaly, 415 00 Larissa, Greece.ORCID 0000-0001-9541-1010
Irene TsilioniDepartment of Immunology, Tufts University School of Medicine, Boston, MA 02111, USA.

Funding

Hellenic Thoracic Society 003/2022
6 · The paper itself

Abstract

backgroundOnly one study has reported the presence of extracellular vesicles (EVs) in COPD patients' sputum. Thus, we aimed to isolate and characterize EVs from COPD and healthy individuals' sputum.

methodsA total of 20 spontaneous sputum samples from COPD patients (m/f: 19/1) and induced sputum samples from healthy controls (m/f: 8/2) were used for EV isolation. The sputum supernatants were resuspended in PBS, precleared by centrifugation at 800×

resultsThe EVs had a spherical shape and their mean diameter in the COPD patients was significantly greater than in the controls. Enrichment of the EV markers, CD9 and CD81, were detected in both the healthy and COPD individuals. Total EV-associated protein was significantly increased in the COPD patients compared to the controls. ROC analysis showed that total EV-associated protein in the sputum could be used to differentiate between the controls and COPD patients, with a sensitivity of 80% and a specificity of 70% at a cut-off point of 55.59 μg/mL (AUC = 0.8150).

conclusionsEVs were detectable in both the COPD and healthy individuals' sputum. The ratio of EVs in the 150-200 nm range was twice as high in the COPD patients than in the controls. The COPD patients' sputum contained increased total EV-associated protein as compared to controls, highlighting their value as a new source of specific exoproteins.

Indexed as

biomarkersCOPDexosomesextracellular vesicleslungsputum

Identifiers

PMID39202011
PMCPMC11355697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.